Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes

References

• Ciurea SO, Cao K, Fernandez-Vina M, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2018;53:521–534. doi:10.1038/s41409-017-0062-8.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Socie G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica. 2010;95:976–982. doi:10.3324/haematol.2009.018267.
   PubMed Web of Science ®Google Scholar
• Ozdemir ZN, Civriz Bozdağ S. Graft failure after allogeneic hematopoietic stem cell transplantation. Transfus Apher Sci. 2018;57:163–167. doi:10.1016/j.transci.2018.04.014.
   PubMed Web of Science ®Google Scholar
• Forman SJ, Negrin RS, Appelbaum FR. Thomas’ hematopoietic cell transplantation: stem cell transplantation. 5th ed. 2016. John Wiley & Sons, Ltd.
   Google Scholar
• Alchalby H, Yunus DR, Zabelina T, et al. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2016;51:1223–1227. doi:10.1038/bmt.2016.98.
   PubMed Web of Science ®Google Scholar
• Kong Y. Poor graft function after allogeneic hematopoietic stem cell transplantation—an old complication with new insights⋆. Semin Hematol. 2019;56:215–220. doi:10.1053/j.seminhematol.2018.08.004.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Gao F, Shi J, et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1898–1907. doi:10.1016/j.bbmt.2019.05.036.
   PubMed Web of Science ®Google Scholar
• Shi MM, Kong Y, Song Y, et al. Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood. 2016;128:2988–2999. doi:10.1182/blood-2016-03-702803.
   PubMed Web of Science ®Google Scholar
• Sun Y-Q, He G-L, Chang Y-J, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol. 2015;94:1699–1705. doi:10.1007/s00277-015-2440-x.
   PubMed Web of Science ®Google Scholar
• Chang Y-J, Zhao X-Y, Xu L-P, et al. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol. 2015;8. doi:10.1186/s13045-015-0182-9.
   Web of Science ®Google Scholar
• Ferra C, Sanz J, Diaz-Perez MA, et al. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leuk Lymphoma. 2015;56:656–662. doi:10.3109/10428194.2014.930849.
   PubMed Web of Science ®Google Scholar
• Doring M, Cabanillas Stanchi KM, Feucht J, et al. Ferritin as an early marker of graft rejection after allogeneic hematopoietic stem cell transplantation in pediatric patients. Ann Hematol. 2016;95:311–323. doi:10.1007/s00277-015-2560-3.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Song J, Jiang Z, et al. Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation. Int J Med Sci. 2014;11:652–657. doi:10.7150/ijms.6337.
   PubMed Web of Science ®Google Scholar
• Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22:4–10. doi:10.1016/j.bbmt.2015.09.001.
   PubMed Web of Science ®Google Scholar
• Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2012;48:537–543.
   PubMedGoogle Scholar
• Cluzeau T, Lambert J, Raus N, et al. Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI. Bone Marrow Transplant. 2016;51:687–691. doi:10.1038/bmt.2015.351.
   PubMedGoogle Scholar
• Mattsson J, Ringdén O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14:165–170. doi:10.1016/j.bbmt.2007.10.025.
   PubMed Web of Science ®Google Scholar
• Nakasone H, Shigeo F, Yakushijin K, et al. Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. Am J Hematol. 2017;92. doi:10.1002/ajh.24613.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang H, Zhou J, et al. Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation. Ther Adv Hematol. 2020;11:2040620720948743. doi:10.1177/2040620720948743.
   Web of Science ®Google Scholar
• Dominietto A, Raiola AM, van Lint MT, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 2001;112:219–227. doi:10.1046/j.1365-2141.2001.02468.x.
   PubMed Web of Science ®Google Scholar
• Shimomura Y, Hara M, Katoh D, et al. Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol. 2018;97:1049–1056. doi:10.1007/s00277-018-3278-9.
   PubMed Web of Science ®Google Scholar
• Akpek G, Pasquini MC, Logan B, et al. Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplant. 2012;48:825–831. doi:10.1038/bmt.2012.249.
   PubMedGoogle Scholar
• Mainardi C, Ebinger M, Enkel S, et al. CD34(+) selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. Br J Haematol. 2018;180:90–99. doi:10.1111/bjh.15012.
   PubMed Web of Science ®Google Scholar
• Liu X, Wu M, Peng Y, et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant. 2014;23:1087–1098. doi:10.3727/096368912X661319.
   PubMed Web of Science ®Google Scholar
• Tang C, Chen F, Kong D, et al. Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag. J Hematol Oncol. 2018;11. doi:10.1186/s13045-018-0649-6.
   Web of Science ®Google Scholar
• Marotta S, Marano L, Ricci P, et al. Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplant. 2019;54:1346–1353. doi:10.1038/s41409-019-0442-3.
   PubMed Web of Science ®Google Scholar
• Kong Y, Wang Y, Zhang YY, et al. Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Adv. 2019;3:1303–1317. doi:10.1182/bloodadvances.2018029454.
   PubMed Web of Science ®Google Scholar